| Immunobiological characterization of cancer stem cells isolated from glioblastoma patients T Di Tomaso, S Mazzoleni, E Wang, G Sovena, D Clavenna, A Franzin, ... Clinical Cancer Research 16 (3), 800-813, 2010 | 379 | 2010 |
| Novel technologies and emerging biomarkers for personalized cancer immunotherapy J Yuan, PS Hegde, R Clynes, PG Foukas, A Harari, TO Kleen, P Kvistborg, ... Journal for immunotherapy of cancer 4, 1-25, 2016 | 268 | 2016 |
| Human NK cells selective targeting of colon cancer–initiating cells: a role for natural cytotoxicity receptors and MHC class I molecules R Tallerico, M Todaro, S Di Franco, C Maccalli, C Garofalo, R Sottile, ... The Journal of Immunology 190 (5), 2381-2390, 2013 | 266 | 2013 |
| Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients. A Anichini, C Maccalli, R Mortarini, S Salvi, A Mazzocchi, P Squarcina, ... The Journal of experimental medicine 177 (4), 989-998, 1993 | 259 | 1993 |
| Defining the critical hurdles in cancer immunotherapy BA Fox, DJ Schendel, LH Butterfield, S Aamdal, JP Allison, PA Ascierto, ... Journal of translational medicine 9, 1-15, 2011 | 190 | 2011 |
| Immunology and immunotherapy of colorectal cancer P Dalerba, C Maccalli, C Casati, C Castelli, G Parmiani Critical reviews in oncology/hematology 46 (1), 33-57, 2003 | 180 | 2003 |
| Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2. 1-restricted immune repertoire to melanoma. A Anichini, R Mortarini, C Maccalli, P Squarcina, K Fleischhauer, ... Journal of immunology (Baltimore, Md.: 1950) 156 (1), 208-217, 1996 | 174 | 1996 |
| Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis W Hendrickx, I Simeone, S Anjum, Y Mokrab, F Bertucci, P Finetti, ... Oncoimmunology 6 (2), e1253654, 2017 | 149 | 2017 |
| Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study AM Di Giacomo, PA Ascierto, P Queirolo, L Pilla, R Ridolfi, M Santinami, ... Annals of Oncology 26 (4), 798-803, 2015 | 143 | 2015 |
| Immunogenomic classification of colorectal cancer and therapeutic implications J Roelands, PJK Kuppen, L Vermeulen, C Maccalli, J Decock, E Wang, ... International journal of molecular sciences 18 (10), 2229, 2017 | 140 | 2017 |
| Immunology of cancer stem cells in solid tumours. A review C Maccalli, A Volontè, C Cimminiello, G Parmiani European journal of cancer 50 (3), 649-655, 2014 | 133 | 2014 |
| Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan … M Sensi, C Traversari, M Radrizzani, S Salvi, C Maccalli, R Mortarini, ... Proceedings of the National Academy of Sciences 92 (12), 5674-5678, 1995 | 132 | 1995 |
| Recommendations from the iSBTc-SITC/FDA/NCI workshop on immunotherapy biomarkers LH Butterfield, AK Palucka, CM Britten, MV Dhodapkar, L Håkansson, ... Clinical Cancer Research 17 (10), 3064-3076, 2011 | 125 | 2011 |
| CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances KM Maalej, M Merhi, VP Inchakalody, S Mestiri, M Alam, C Maccalli, ... Molecular Cancer 22 (1), 20, 2023 | 123 | 2023 |
| Expression of cytokine genes, including IL-6, in human malignant melanoma cell lines MP Colombo, C Maccalli, S Mattei, C Melani, M Radrizzani, G Parmiani Melanoma research 2 (3), 181-190, 1992 | 119 | 1992 |
| Cancer-initiating cells from colorectal cancer patients escape from T cell–mediated immunosurveillance in vitro through membrane-bound IL-4 A Volonté, T Di Tomaso, M Spinelli, M Todaro, F Sanvito, L Albarello, ... The Journal of Immunology 192 (1), 523-532, 2014 | 115 | 2014 |
| T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain … M Sensi, S Salvi, C Castelli, C Maccalli, A Mazzocchi, R Mortarini, ... The Journal of experimental medicine 178 (4), 1231-1246, 1993 | 101 | 1993 |
| The role of cancer stem cells in the modulation of anti-tumor immune responses C Maccalli, KI Rasul, M Elawad, S Ferrone Seminars in cancer biology 53, 189-200, 2018 | 97 | 2018 |
| Immunomodulating and immunoresistance properties of cancer-initiating cells: implications for the clinical success of immunotherapy C Maccalli, G Parmiani, S Ferrone Immunological investigations 46 (3), 221-238, 2017 | 96 | 2017 |
| NKG2D engagement of colorectal cancer‐specific T cells strengthens TCR‐mediated antigen stimulation and elicits TCR independent anti‐tumor activity C Maccalli, D Pende, C Castelli, MC Mingari, PF Robbins, G Parmiani European journal of immunology 33 (7), 2033-2043, 2003 | 80 | 2003 |
Andrea AnichiniFondazione IRCCS Istituto Nazionale dei Tumori, Milan在 istitutotumori.mi.it 的电子邮件经过验证
